Market data
Select a section
Hikma Pharmaceuticals
(HIK)
Sector: Pharmaceuticals & Biotechnology
1,955.00p
5.00p 0.26
Last updated: 09:33:12
1 day chart
6 month chart
Today's buy and sell prices
| The price at which you can buy a share or investment. It is usually higher than the bid (sell) price. It’s the price you are being offered. Offer | 1,957.00p |
|---|---|
| The price at which you can sell a share or investment. It is lower than the offer (buy) price. Bid | 1,955.00p |
| The difference between the bid and offer prices expressed as a percentage. When you buy shares you pay a higher price than you get when you sell them. The difference between these prices is the profit made by the market maker who puts the deals together. Spread | 0.10 |
Today's trading
| Range The lowest and the highest price a share has reached in the trading day. | 1,947.53p-1,974.00p |
|---|---|
| The lowest and the highest price a share has reached in the trading day. Volume | 39,873.00 |
| The lowest and the highest price a share has reached in the trading day. Today's open | 1,964.00p |
| At the end of the trading day there is an official closing price for every share. The previous session’s close is used as the base to calculate the following day’s price changes. Previous close | 1,872.00p |
Yearly summary
| The highest and lowest prices the shares have traded at over a rolling 52-week period. It gives you a good indication of how the share price is performing now relative to its recent past performance. 52wk range | 1,722.50p-2,088.00p |
|---|
Fundamentals and health
| A measure of the company's worth on the stock market. We display the previous closing share price multiplied by the number of shares in issue. Market capitalisation | £4,337.88 |
|---|---|
| The number of shares a company has in circulation, in millions. Shares in issue | 221.89 |
| The main valuation used by investors and a way of gauging whether a company's share price is cheap or expensive compared to competitors. You get PE by dividing the share price by the earnings per share (EPS). Our figure is last basic unadjusted - reported - annual EPS / current share price x 100. Companies also quote adjusted EPS figures to remove the effect of one-off exceptional figures from the profit figures. There is debate among investors as to whether this should be used. We use basic EPS – the purest figure. PE ratio | 10 |
| PEG ratio | 0.4 |
| An important ratio for showing how much profit after tax and other deductions (net profit) is actually being earned per share. You divide the net profit by the number of shares in issue. Expressed in pence per share. Looking at whether the EPS is rising or falling over time is one of the most important indicators of whether a company is really making money for its shareholders. Our figure is undiluted, meaning it is not adjusted for exceptional costs. EPS | 86.00¢ |
| Earnings per share growth illustrates the growth of earning per share over the last two reporting periods. It helps investors identify stocks that are increasing or decreasing in profitability. A minus sign indicates negative growth. EPS growth | 23 |
| Return on capital employed measures a company's profitability in relation to how much capital is invested in the business. Generally, the higher the figure the better but with all these ratios it is best to compare companies from the same sector. A high double digit figure may mean a company has an advantage over its competitors because of a unique product but an oil company, for example, will have higher capital outlay than an online retailer. Our formula: [Pre-tax profit / (total assets – short-term liabilities)] * 100 ROCE | 15.82 |
| Also known as the acid test ratio, it's a quick guide to how well a company can pay its short-term debts. Above 1 is considered healthy. A ratio of 1.5 would mean the company has £1.50 of liquid (accessible) assets to cover each £1 of debt (current liabilities). Formula: Current assets minus inventory / current liabilities. Quick ratio | 0.90 |
| Indicates whether a company can convert assets into cash to pay its debts within the next 12 months. It is calculated as current assets / current liabilities for the same period but will display as '0' for companies such as banks that don't distinguish between short and long-term liabilities. Current ratio | 1.57 |
| The amount of money a company paid to a shareholder for each share they own over the past 12 months, expressed in pence. Total dividends per share | 72.00¢ |
| The dividends paid per share over the past 12 months (interim plus final) as a percentage of the share price. Our figure includes recurring special dividends. Dividend yield | 3.2 |
| The number of times the dividend could have been paid out from net profits. It is a good indicator of the company's ability to pay the dividend and its level of generosity. Formula: earnings per share / dividends per share. More than 2 is considered healthy, less than 1.5 may hint that a dividend is at risk of being cut. Dividend cover | 3.1 |
| Dividend per share growth | 28.57 |
Hikma Pharmaceuticals Fundamentals
Hikma is an international pharmaceutical company conducting operations through three businesses: generic pharmaceuticals, branded pharmaceuticals and injectable pharmaceuticals. The company sells 113 branded and non-branded generic pharmaceutical products in 34 countries worldwide. The majority of Hikma's operations are in the United States, the Middle East and North Africa Region and Europe.
Hikma Pharmaceuticals Regulatory news
| Date | Time | Headline | Source |
|---|---|---|---|
| 07/11/2024 | 15:30 | Outcome of Audit Tender Process | RNS |
| 07/11/2024 | 07:00 | Trading Statement | RNS |
| 24/10/2024 | 07:00 | 2024 Annual General Meeting Update Statement | RNS |
| 01/10/2024 | 09:45 | Block listing Interim Review | RNS |
| 24/09/2024 | 10:09 | Director/PDMR Shareholding | RNS |
| 10/09/2024 | 07:00 | Hikma completes Xellia acquisition | RNS |
| 13/08/2024 | 09:39 | Director/PDMR Shareholding | RNS |
| 08/08/2024 | 07:00 | Half-year Report | RNS |
| 29/07/2024 | 16:08 | Director Declaration | RNS |
| 15/07/2024 | 07:00 | Notice of Results | RNS |
Hikma Pharmaceuticals Latest trades
Latest trades
| Date | Time | Price | Amount | Value | Type | Buy / sell |
|---|---|---|---|---|---|---|
| 25/11/2024 | 09:30:00 | 1955p | 40 | £782.00 | AT | Sell |
| 25/11/2024 | 09:30:00 | 1955p | 53 | £1,036.15 | AT | Sell |
| 25/11/2024 | 09:28:05 | 1955p | 267 | £5,222.52 | O | Sell |
| 25/11/2024 | 09:28:00 | 1954p | 27 | £527.58 | O | Sell |
| 25/11/2024 | 09:28:00 | 1954p | 26 | £508.04 | O | Sell |
Analysis
| Buy | Sell | Unknown | |
|---|---|---|---|
| Quantity | 107 | 146 | 64 |
| Volume | 26,946 | 12,949 | 4,914 |
| Value | £528,132 | £253,792 | £96,511 |
Hikma Pharmaceuticals Director dealings
| Trade date | Director | Volume / Price | Trade value | Trade type |
|---|---|---|---|---|
| 23/09/2024 | Riad Mishlawi | 509 @ 1,903.00p | £9,686.27 | Dividend Reinvestment |
| 07/05/2024 | Riad Mishlawi | 736 @ 1,979.00p | £14,565.44 | Buy |
| 12/03/2024 | Mazen Darwazah | 13,903 @ 0.00 | 0.00 | Transfer From |
| 12/03/2024 | Mazen Darwazah | 26,812 @ 0.00 | 0.00 | Transfer From |
| 12/03/2024 | Riad Mishlawi | 17,120 @ 0.00 | 0.00 | Transfer From |
| 12/03/2024 | Riad Mishlawi | 22,099 @ 0.00 | 0.00 | Transfer From |
| 12/03/2024 | Said Darwazah | 19,830 @ 0.00 | 0.00 | Transfer From |
| 12/03/2024 | Said Darwazah | 34,652 @ 0.00 | 0.00 | Transfer From |
| 06/06/2023 | Douglas Hurt | 1,500 @ 1,820.00p | £27,300.00 | Buy |
| 17/04/2023 | Mazen Darwazah | 18,831 @ 0.00 | 0.00 | Transfer From |
Hikma Pharmaceuticals Broker views
| Date | Broker | Recomm. | Old target price | New target price | Notes |
|---|---|---|---|---|---|
| 02/09/2024 | Berenberg Bank | buy | 2,100.00p | 2,400.00p | upgrade |
| 12/08/2024 | Berenberg Bank | hold | 2,000.00p | 2,100.00p | reiteration |
| 18/06/2024 | Deutsche | buy | - | 2,750.00p | reiteration |
| 07/05/2024 | Barclays | equal-weight | - | 2,000.00p | reiteration |
| 25/04/2024 | Berenberg Bank | hold | - | 2,000.00p | reiteration |
| 08/04/2024 | Barclays | equal-weight | - | 2,000.00p | reiteration |
| 26/02/2024 | Berenberg Bank | hold | 1,960.00p | 2,000.00p | reiteration |
| 13/11/2023 | RBC Capital Markets | sector perform | - | 2,150.00p | reiteration |
| 16/10/2023 | JP Morgan Cazenove | overweight | - | - | reiteration |
| 03/10/2023 | Citigroup | buy | - | - | reiteration |
Hikma Pharmaceuticals News
| Date | Time | Headline |
|---|---|---|
| 21/08/2024 | 15:41 | Share price winners and losers since the election revealed... |
| 17/06/2024 | 09:41 | Drug company Hikma to buy parts of Danish rival in deal worth up to £146m |
| 28/04/2023 | 19:12 | MARKET REPORT: Prudential stock boosted by Hong Kong sales drive |
| 30/09/2022 | 18:48 | MARKET REPORT: Cruise company Carnival crashes to record low |
| 05/08/2022 | 17:29 | MARKET REPORT: Takeover snub revs up shares in car dealer Pendragon |
| 29/04/2022 | 17:23 | MARKET REPORT: Johnson Matthey soars after US giant buys stake |
| 06/08/2021 | 18:58 | MARKET REPORT: Investors send Hikma Pharmaceuticals sliding |
| 30/04/2021 | 18:46 | MARKET REPORT: Smurfit Kappa makes packet from online boom |
| 17/05/2017 | 17:38 | Sophos shoots to top of FTSE 250 in wake of WannaCry chaos |
| 30/03/2017 | 18:27 | MARKET REPORT: Hayward and Rothschild lose millions |
